BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vincent FB, Bourke P, Morand EF, Mackay F, Bossingham D. Focus on systemic lupus erythematosus in indigenous Australians: towards a better understanding of autoimmune diseases. Intern Med J 2013;43:227-34. [PMID: 23176380 DOI: 10.1111/imj.12039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014;10:365-73. [PMID: 24614588 DOI: 10.1038/nrrheum.2014.33] [Cited by in Crossref: 227] [Cited by in F6Publishing: 208] [Article Influence: 28.4] [Reference Citation Analysis]
2 Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013;24:203-15. [PMID: 23684423 DOI: 10.1016/j.cytogfr.2013.04.003] [Cited by in Crossref: 223] [Cited by in F6Publishing: 209] [Article Influence: 24.8] [Reference Citation Analysis]
3 Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016;12:605-20. [PMID: 27558659 DOI: 10.1038/nrrheum.2016.137] [Cited by in Crossref: 151] [Cited by in F6Publishing: 135] [Article Influence: 25.2] [Reference Citation Analysis]
4 Pan Q, Liu Z, Liao S, Ye L, Lu X, Chen X, Li Z, Li X, Xu YZ, Liu H. Current mechanistic insights into the role of infection in systemic lupus erythematosus. Biomed Pharmacother 2019;117:109122. [PMID: 31226637 DOI: 10.1016/j.biopha.2019.109122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Morand EF, Leech MT. Successes, challenges and developments in Australian rheumatology. Nat Rev Rheumatol 2015;11:430-6. [PMID: 25756549 DOI: 10.1038/nrrheum.2015.22] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
6 Jones SA, Cantsilieris S, Fan H, Cheng Q, Russ BE, Tucker EJ, Harris J, Rudloff I, Nold M, Northcott M, Dankers W, Toh AEJ, White SJ, Morand EF. Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus. Sci Rep 2019;9:15433. [PMID: 31659207 DOI: 10.1038/s41598-019-51864-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Petit A, Dadzie O. Multisystemic diseases and ethnicity: a focus on lupus erythematosus, systemic sclerosis, sarcoidosis and Behçet disease. Br J Dermatol 2013;169:1-10. [DOI: 10.1111/bjd.12533] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hammond ER, Tummala R, Berglind A, Syed F, Wang X, Desta B, Nab H. Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature. BMJ Open 2020;10:e036563. [PMID: 32873668 DOI: 10.1136/bmjopen-2019-036563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Golder V, Hoi A. Systemic lupus erythematosus: an update. Med J Aust 2017;206:215-20. [PMID: 28301792 DOI: 10.5694/mja16.01229] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
10 Cann MP, Sage AM, McKinnon E, Lee SJ, Tunbridge D, Larkins NG, Murray KJ. Childhood Systemic Lupus Erythematosus: Presentation, management and long-term outcomes in an Australian cohort. Lupus 2022;:9612033211069765. [PMID: 35037500 DOI: 10.1177/09612033211069765] [Reference Citation Analysis]
11 Birrell JM, Gunathilake M, Singleton S, Williams S, Krause V. Characteristics and Impact of Disseminated Gonococcal Infection in the "Top End" of Australia. Am J Trop Med Hyg 2019;101:753-60. [PMID: 31392956 DOI: 10.4269/ajtmh.19-0288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Raymond WD, Lester S, Preen DB, Keen HI, Inderjeeth CA, Furfaro M, Nossent JC. Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study. Lupus Sci Med 2021;8:e000539. [PMID: 34667085 DOI: 10.1136/lupus-2021-000539] [Reference Citation Analysis]
13 Bohensky M, Tacey M, Brand C, Sundararajan V, Wicks I, Van Doornum S. Statin initiation and treatment non-adherence following a first acute myocardial infarction in patients with inflammatory rheumatic disease versus the general population. Arthritis Res Ther 2014;16:443. [PMID: 25256139 DOI: 10.1186/s13075-014-0443-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Nikpour M, Bridge JA, Richter S. A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: identifying areas of unmet need. Intern Med J 2014;44:1170-9. [PMID: 25169712 DOI: 10.1111/imj.12568] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
15 Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F, Morand EF. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunology 2019;8:e01047. [PMID: 31024730 DOI: 10.1002/cti2.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Wongseelashote S, Tayal V, Bourke PF. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016. Intern Med J 2018;48:165-72. [PMID: 28742259 DOI: 10.1111/imj.13554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]